hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.2478/acph-2014-0029

Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat

MAGDALENA JASIŃSKA-STROSCHEIN ; Department of Biopharmacy, Medical University of Łódź, Łódź, Poland
JACEK OWCZAREK ; Department of Biopharmacy, Medical University of Łódź, Łódź, Poland
ANNA WESOŁOWSKA ; Department of Biopharmacy, Medical University of Łódź, Łódź, Poland
DARIA ORSZULAK-MICHALAK

Puni tekst: engleski, pdf (564 KB) str. 345-354 preuzimanja: 488* citiraj
APA 6th Edition
JASIŃSKA-STROSCHEIN, M., OWCZAREK, J., WESOŁOWSKA, A. i ORSZULAK-MICHALAK, D. (2014). Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat. Acta Pharmaceutica, 64 (3), 345-354. https://doi.org/10.2478/acph-2014-0029
MLA 8th Edition
JASIŃSKA-STROSCHEIN, MAGDALENA, et al. "Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat." Acta Pharmaceutica, vol. 64, br. 3, 2014, str. 345-354. https://doi.org/10.2478/acph-2014-0029. Citirano 19.10.2019.
Chicago 17th Edition
JASIŃSKA-STROSCHEIN, MAGDALENA, JACEK OWCZAREK, ANNA WESOŁOWSKA i DARIA ORSZULAK-MICHALAK. "Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat." Acta Pharmaceutica 64, br. 3 (2014): 345-354. https://doi.org/10.2478/acph-2014-0029
Harvard
JASIŃSKA-STROSCHEIN, M., et al. (2014). 'Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat', Acta Pharmaceutica, 64(3), str. 345-354. https://doi.org/10.2478/acph-2014-0029
Vancouver
JASIŃSKA-STROSCHEIN M, OWCZAREK J, WESOŁOWSKA A, ORSZULAK-MICHALAK D. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat. Acta Pharm. [Internet]. 2014 [pristupljeno 19.10.2019.];64(3):345-354. https://doi.org/10.2478/acph-2014-0029
IEEE
M. JASIŃSKA-STROSCHEIN, J. OWCZAREK, A. WESOŁOWSKA i D. ORSZULAK-MICHALAK, "Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat", Acta Pharmaceutica, vol.64, br. 3, str. 345-354, 2014. [Online]. https://doi.org/10.2478/acph-2014-0029

Sažetak
There is considerable interest in the pleiotropic effects of statins and their potential role in the treatment of pulmonary hypertension. Previous experimental findings indicate that a combination of lipophilic statins with phosphodiesterase type-5 inhibitor, sildenafil, can offer preventive effects on rat monocrotaline-induced pulmonary hypertension. The present study is aimed to assess whether therapeutic regimen provides any benefits. Seven days after pulmonary hypertension induction, hydrophilic rosuvastatin and sildenafil were given 14 days to male Wistar outbred rats. Right ventricular pressure, right ventricle mass and three biomarkers were evaluated after 21 days: brain natriuretic peptide, high-density lipoprotein cholesterol and vascular endothelial growth factor. The present study demonstrates that administration of hydrophilic statin with sildenafil results in reduction of pulmonary vascular remodeling and right ventricular pressure. The results of biochemical measurements may suggest that statins play a positive role in right ventricle function or the process of angiogenesis in pulmonary hypertension development.

Ključne riječi
rosuvastatin; sildenafil; combination therapy; pulmonary hypertension; hemodynamic parameters

Hrčak ID: 121073

URI
https://hrcak.srce.hr/121073

Posjeta: 659 *